<DOC>
	<DOC>NCT00749411</DOC>
	<brief_summary>The purpose of this study is the evaluate the safety and tolerability of repeat dosing of the combination of inhaled GSK233705 and GW642444 administered once-daily in subjects with COPD.</brief_summary>
	<brief_title>Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Muscarinic Antagonists</mesh_term>
	<criteria>male and females 40 to 80 years of age (inclusive) COPD diagnosis Current or previous smokers with a cigarette smoking history of at least 10 pack Postalbuterol FEV1/FVC of 0.70 or less Postalbuterol FEV1 of 35% to 80% (inclusive) Pregnant or lactating females current diagnosis of asthma respiratory disorders other than COPD clinically significant cardiovascular, neurological, psychiatric, renal, immunological, endocrine, or hematological abnormalities that are uncontrolled clinically significant sleep apnea previous lung resection surgery clinically significant abnormalities confirmed by chest xray that are not related to COPD hospitalization for COPD within 3 months of screening use of antibiotics for lower respiratory tract infection within 6 months of screening abnormal and clinically significant 12lead ECG findings current malignancy in remission for less that 5 years medical conditions that would contraindicate the use of anticholinergics positive hepatitis B or C test history of alcohol or drug abuse unable to withhold albuterol for 6 or more hours use of long term oxygen therapy conditions that would limit the validity of informed consent use of GW642444 or GSK233705 in previous studies use of an investigation drug with 30 days of screening use of inhaled corticosteroids (ICS) at a dose greater than 1000mcg of fluticasone propionate or equivalent hypersensitivity to betaagonists concurrent use of longacting betaagonists (LABA) or longacting muscaring antagonists, LABA/ICS combination products, cytochrome p450 inhibitors, oral or depot corticosteroids, theophyllines, oral beta agonists, oral leukotrine modulators, inhaled short acting anticholinergics.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>COPD</keyword>
	<keyword>long-acting beta agonist</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Chronic Bronchitis</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>long acting muscarinic antagonist</keyword>
</DOC>